January 2024 in “Circulation” This commentary explores the role of PCSK9 as a target for drug development, underscoring that individuals with PCSK9 loss-of-function mutations experience significantly lowered LDL cholesterol levels and reduced coronary events, suggesting that full inactivation of PCSK9 is effective and safe.
September 2025 in “Arthritis Research & Therapy” In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.
391 citations
,
September 2015 in “Journal of Clinical Lipidology” This document extends previous recommendations by the National Lipid Association for managing dyslipidemia, focusing on lifestyle therapies, special patient groups, and strategies to enhance adherence and patient outcomes.
112 citations
,
May 2019 in “Pharmacological Research” This review discusses the isolation, structure, and bioactivity of lignans and neolignans from 2016 to mid-2018, reporting no new clinical results but highlighting their potential protective properties against diseases such as cancer and neurodegeneration.
7 citations
,
July 2019 in “Scientific Reports” In this study, anti-androgenic therapy with finasteride for prostate disease was associated with reduced cardiac hypertrophy in heart failure patients, encouraging further investigation in larger cohorts.
